A Phase II Study of Avastin Plus Rituximab for Patients With Relapsed and Chemotherapy- or Rituxan-Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Trial Profile

A Phase II Study of Avastin Plus Rituximab for Patients With Relapsed and Chemotherapy- or Rituxan-Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2014

At a glance

  • Drugs Bevacizumab (Primary) ; Rituximab (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Apr 2012 Actual patient number (13) added as reported by ClinicalTrials.gov.
    • 01 Sep 2009 Actual end date (Sep 2007) added as reported by ClinicalTrials.gov.
    • 01 Sep 2009 Actual patient number (13) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top